Hormonal
Post-bariatric patients with insufficient weight loss or weight regain achieve significant additional weight loss and comorbidity improvement when treated with GLP-1 receptor agonists (semaglutide or dulaglutide).
If you have had bariatric surgery and are not losing enough weight or are gaining it back, ask your doctor about GLP-1 medications like semaglutide or dulaglutide. These drugs can help you lose more weight and improve health conditions like high blood pressure and sleep apnea. They are taken as weekly injections and are generally well-tolerated, though nausea is a common side effect.
arGLP-1 are effective and safe for managing IWL or WR after BS, leading to significant weight loss, comorbidity improvement, and sustained %TWL.
Why this rating
The study is a retrospective analysis with a relatively small sample size (N=100, N=56 for 1-year follow-up) and lacks a control group, limiting causal inference.
Source
Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery
Hussein Abdallah et al. · Obesity Surgery · 2025
DOI 10.1007/s11695-025-08210-y
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →